MagForce is moving forward with its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer. In Germany, Magforce has six centres commercially capable (three utilised, c50 patients to date) of treating glioblastoma (GBM) patients. To accelerate uptake of NanoTherm treatment in Europe, we expect Magforce to look to expand from Germany into other countries over six to 18 months. In the US, its subsidiary Magforce USA is in talks with the FDA to initiate a planned clinical trial in prostate cancer patients (potential launch in 2018). The company expects the trial to initiate in mid-2017; data are expected 12 months later. Our valuation is €225m (€8.8/share).

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central